LON:IBT International Biotechnology (IBT) Share Price, News & Analysis GBX 970 -6.00 (-0.61%) As of 12:15 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About International Biotechnology Stock (LON:IBT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IBT alerts:Sign Up Key Stats Today's Range 966.80▼ 98850-Day Range 848.65▼ 1,00552-Week Range 550▼ 1,010Volume42,238 shsAverage Volume58,968 shsMarket Capitalization£308.73 millionP/E RatioN/ADividend Yield3.26%Price TargetN/AConsensus RatingN/A Company Overview The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. Investments may also be made in related sectors such as medical devices and healthcare services. While the Company’s portfolio is held as one pool of assets, for operational purposes there is a quoted portfolio and an unquoted portfolio. The portfolio is diversified by geography, industry sub-sector and investment size with no single investment in a company normally accounting for more than 15% of the portfolio at the time of investment. The portfolio is split between large, mid and small-capitalisation companies, primarily quoted on stock exchanges in North America, where the most established and commercial biotech and other life sciences companies and companies operating in related sectors are based, though investments will also be made in Europe, Asia and Australia. Investments may also be made into unquoted companies and into funds not quoted on a stock exchange, including venture capital funds. This may include funds managed by the Investment Manager and/or members of its group. The primary purpose of investment in unquoted funds will be to gain exposure to unquoted companies. The Company may invest through equities, index-linked securities and debt securities, cash deposits, money market instruments and foreign currency exchange transactions. Forward or derivative transactions are not used by the Company. The Company may borrow from time to time to exploit specific investment opportunities, rather than to apply long-term structural gearing to the Company’s portfolio of investments. Read More Receive IBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for International Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBT Stock News HeadlinesNew Bill: Senator Tim Sheehy introduces S. 4491: Biodefense Diplomacy Enhancement ActMay 19 at 11:50 AM | quiverquant.comQIBT portfolio manager says KalVista deal signals Biotech 2.0 growthApril 30, 2026 | finance.yahoo.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 19 at 1:00 AM | Brownstone Research (Ad)International Biotechnology Trust expects more M&A after Soleno dealApril 7, 2026 | lse.co.ukWhat the trend in M&A means for International Biotechnology Trust - ICYMIMarch 21, 2026 | uk.finance.yahoo.comWhy biotech is back: IBT portfolio manager’s viewMarch 18, 2026 | finance.yahoo.comDyadic International, Inc.: Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT BioservicesMarch 16, 2026 | finanznachrichten.deServier acquires International Biotech's Day One for USD2.5 billionMarch 9, 2026 | lse.co.ukSee More Headlines IBT Stock Analysis - Frequently Asked Questions How have IBT shares performed this year? International Biotechnology's stock was trading at GBX 964 at the start of the year. Since then, IBT shares have increased by 0.6% and is now trading at GBX 970. How were International Biotechnology's earnings last quarter? International Biotechnology (LON:IBT) posted its quarterly earnings results on Tuesday, May, 12th. The company reported ($4.83) earnings per share for the quarter. The firm had revenue of $0.24 million for the quarter. International Biotechnology had a net margin of 82.27% and a trailing twelve-month return on equity of 27.35%. How do I buy shares of International Biotechnology? Shares of IBT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of International Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that International Biotechnology investors own include Vanquis Banking Group (PFG), 1724525 (ADN.L) (ADN), abrdn New India Investment Trust (ANII), The Berkeley Group (BKG), GLI Finance (GLIF), Hurricane Energy (HUR) and Oxford Pharmascience Group (OXP). Company Calendar Last Earnings5/12/2026Today5/19/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorFinancial Services Industry Asset Management Sub-IndustryN/A Current SymbolLON:IBT CIKN/A Webwww.ibtplc.com Phone44 20 7421 7070FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (3.29) Trailing P/E RatioN/A Forward P/E Ratio1,027.98 P/E GrowthN/ANet Income£37.91 million Net Margins82.27% Pretax MarginN/A Return on Equity27.35% Return on Assets3.57% Debt Debt-to-Equity Ratio9.43 Current Ratio0.11 Quick Ratio0.32 Sales & Book Value Annual Sales-£175 thousand Price / Sales-1,764.18 Cash FlowGBX 6.23 per share Price / Cash Flow155.74 Book ValueGBX 766.24 per share Price / Book1.27Miscellaneous Outstanding Shares31,828,000Free FloatN/AMarket Cap£308.73 million OptionableNot Optionable Beta0.32 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (LON:IBT) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding International Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share International Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
